ArticleOpen life sciences2025
Construction of a microbial abundance prognostic scoring model based on intratumoral microbial data for predicting the prognosis of lung squamous cell carcinoma.
Article in Open life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of lung squamous cell carcinoma (LUSC) is associated with the intratumoral microbiota. To facilitate faster clinical decisions and predict patient prognosis, we constructed an intratumoral microbial abundance prognostic scoring (MAPS) model for LUSC and analyzed its prognostic performance. Data on the LUSC tumor microbiome, patient survival, and clinical information were downloaded from The Cancer Microbiome Atlas and The Cancer Genome Atlas databases. Differentially abundant microbial genera in LUSC tumors were analyzed, and their prognostic value was evaluated. The differential abundance of key genera in the MAPS model was validated using lung adenocarcinoma (LUAD) tumors and normal tissues. Of 52 microbial genera with increased abundance and 437 with decreased abundance in LUSC tumors, 462 were highly related to the disease. Seven of 13 genera that were significantly related to prognosis were selected to construct the MAPS model. The MAPS risk grouping was identified as a prognostic risk factor for LUSC. Among the seven genera in the MAPS model,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.